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ORIGINAL INVESTIGATION
Effects of Conjugated Equine Estrogen
on Health-Related Quality of Life
in Postmenopausal Women With Hysterectomy
Results From the Women’s Health Initiative Randomized Clinical Trial
Robert L. Brunner, PhD; Margery Gass, MD; Aaron Aragaki, MS; Jennifer Hays, PhD; Iris Granek, MD;
Nancy Woods, PhD, RN; Ellen Mason, MD; Robert Brzyski, MD, PhD; Judith Ockene, PhD; Annlouise Assaf, PhD;
Andrea LaCroix, MPH, PhD; Karen Matthews, PhD; Robert Wallace, MD;
for the Women’s Health Initiative Investigators
Background: The Women’s Health Initiative (WHI)
clinical trial of conjugated equine estrogens (CEEs), in-
volving 10 739 postmenopausal women with hysterec-
tomy, aged 50 to 79 years, was stopped early owing to
lack of overall health benefit and increased risk of stroke.
Because CEE is still prescribed for treatment of meno-
pausal symptoms and prevention of osteoporosis, it is im-
portant to understand the overall impact of this therapy
on health-related quality of life (HRQOL).
Methods: All participants completed 6 specific mea-
sures of quality of life at baseline and 1 year, and a sub-
sample (n=1189) also completed the questions 3 years
after randomization. Changes in scores were analyzed for
treatment effect.
Results: Randomization to CEE was associated with a
statistically significant but small reduction in sleep
disturbance at year 1 compared with baseline (mean
benefit, 0.4 points on a 20-point scale) and a statisti-
cally significant but small negative effect on social
functioning (mean effect, −1.3 points on a 100-point
scale). There were no significant improvements due to
CEE in the areas of general health, physical function-
ing, pain, vitality, role functioning, mental health,
depressive symptoms, cognitive function, or sexual
satisfaction at year 1. A subgroup examined 3 years
after baseline had no significant benefits for any
HRQOL outcomes. Among women aged 50 to 54 years
with moderate to severe vasomotor symptoms at base-
line, CEE did not improve any of the HRQOL vari-
ables at year 1.
Conclusion: In this trial of postmenopausal women
with prior hysterectomy, oral CEE did not have a
clinically meaningful effect on HRQOL.
Arch Intern Med. 2005;165:1976-1986
R ESULTS OF RECENTLY PUB-lished large, randomizedclinical trials have failed tosupport protective effects oforal estrogen therapy alone
or estrogen plus progestin therapy on car-
diovascular disease when administered to
postmenopausal women.1-3 Findings of the
Women’s Health Initiative (WHI)4 dem-
onstrated that, compared with placebo,
women taking conjugated equine estro-
gens (CEEs) were at increased risk for
stroke and deep vein thrombosis and at de-
creased risk for osteoporotic fractures. The
global risk-benefit profile was neutral in
the CEE treatment group, and the planned
8.5-year randomized clinical trial (RCT)
was stopped after an average of 6.8 years
of follow-up (range, 5.7-10.7 years).
Although the parallel WHI trial of
CEE and medroxyprogesterone acetate
(CEEMPA) and other results showed
that active treatment produced relief from
vasomotor symptoms, the health-related
quality of life (HRQOL) effects were lim-
ited to modest changes in physical func-
tioning, sleep disturbance, and bodily pain
that were considered too small to be of
clinical significance on a population
basis.5-7
The origin of the HRQOL concept has
often been attributed to the World Health
Organization position that health is a “state
of complete physical, mental and social
well-being and not merely the absence of
infirmity and disease.”8 Health-related
quality of life (QOL) limits the influ-
ences on QOL to medical conditions
and/or their treatment.9
Typical self-assessment of HRQOL ex-
amines aspects of functioning that may re-
late to disease symptoms, disability, and
outcome.10 Many HRQOL instruments tar-
get symptoms for specific medical condi-
Author Affiliations are listed at
the end of this article.
Group Information: A complete
list of investigators in the
Women’s Health Initiative
appears in the box on pages
1984 and 1985.
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tions.11 However, the concept is also more broadly de-
fined as encompassing multiple domains such as physical
health and functioning, emotional functioning, social
functioning, and role limitations.12 This approach and a
single summary measure, ie, “global” QOL, were used
herein and in the earlier CEEMPA RCT. They have been
widely validated.13-15 Quality-of-life benefit is a consid-
eration in the decision to use hormone therapy.16,17
Several recent reports have found some domains of
HRQOL to be affected by the transition from before to
after menopause, with depressive symptoms tending not
to be affected.18-23 Women before the menopause transi-
tion compared with women who had begun the transi-
tion differed in reports of pain, role limitations, and vi-
tality, but adjustments for symptoms (leaking urine,
vaginal dryness, night sweats, and hot flashes) and other
variables reduced differences in HRQOL to nonsignifi-
cance in a large cross-sectional study.23,24 Estrogen alone
as a postmenopausal hormone treatment continues to be
offered for vasomotor symptom reduction, with collat-
eral improvement reported in depression,25 sexual func-
tioning,26 and cognitive functioning,27 all of which are
components of HRQOL and an influence on global QOL.
However, objective evidence of efficacy, particularly from
longitudinal studies of menopause28 or randomized trials,
have been inconsistent.29,30 The present RCT is a ran-
domized, double-blind, placebo-controlled study con-
ducted in women with prior hysterectomy, which elimi-
nates a major adverse effect of hormone therapy (uterine
bleeding). Other adverse effects such as breast tender-
ness, bloating, and moodiness, which are sometimes at-
tributed to the use of a progestin, also are reduced be-
cause progestin was not used in this study. Thus, the WHI
CEE trial provides an excellent opportunity to evaluate
HRQOL benefits of estrogen in a large, diverse popula-
tion of relatively healthy, postmenopausal women, some
with symptoms associated with estrogen therapy with-
drawal and others nonsymptomatic.
METHODS
The eligibility criteria, recruitment procedures, and main study
outcomes have been published previously.4,31,32 Briefly, women
aged 50 to 79 years with hysterectomy more than 3 months ear-
lier (with or without oophorectomy) were potentially eligible
for this RCT. Participation in the WHI was precluded if a medi-
cal condition predicted survival of less than 3 years or if there
were diagnoses of previous breast cancer or melanoma, other
cancer within the past 10 years (except nonmelanoma skin can-
cer), low hematocrit or platelet counts, or any condition that
would interfere with acceptable adherence and retention (eg,
alcoholism or dementia). A 3-month washout of any prevail-
ing hormone therapy was required before starting data collec-
tion, screening, and enrollment. Women who reported mod-
erate or severe menopausal symptoms during the washout period
were not excluded but were discouraged from participating.
Initial consent forms, questionnaires, fasting blood draws,
physical measurements, and breast and pelvic examinations were
completed at 3 screening visits. As part of the screening pro-
cess, women took placebo pills for at least 4 weeks to assess
compliance with pill taking. Then, eligible participants were
randomized to CEE (0.625 mg) or matching placebo treat-
ment. Participants and clinic staff were blinded to the study pill
assignments. Clinic visits occurred 6 and 12 months (year 1
visit) after randomization, and annually thereafter. The base-
line questionnaires were completed at the year 1 visit for all
participants and, for an 8.6% subsample (n=1189), at the year
3 visit. The 8.6% subsample was selected to have a larger pro-
portion of ethnic minority participants than the overall co-
hort. The National Institutes of Health, Bethesda, Md, and the
institutional review boards of all participating institutions ap-
proved the protocol and consent forms.
ASSESSMENT OF HRQOL AND
FUNCTIONAL STATUS
Quality of life/functional status was assessed using the RAND
36-Item Health Survey (RAND36).33,34 The RAND36 has 8 sub-
scales, each with a score range of 0 to 100 (with higher scores
being better), that assess general health, physical functioning,
role limitations due to physical health, bodily pain, energy and
fatigue (vitality), role limitations due to emotional/mental prob-
lems, social functioning, and emotional/mental health and a
stand-alone health transition question. Although the RAND36
contains the same items as the 36-item Medical Outcomes Study
Short Form, it uses a slightly different scoring algorithm for 2
of the 8 subscales.
GLOBAL QOL
Global QOL was assessed by a single item (“Overall, how would
you rate your quality of life?”) with an 11-point response scale
(0 indicates “as bad or worse than being dead” and 10, “best
quality of life”) that was reduced, for analysis, to 4 categories
corresponding to poor (0-4), moderate (5-7), good (8), and ex-
cellent (9-10). The categories were chosen a priori and mirror
those used in the Study of Women Across the Nation HRQOL.23
SLEEP QUALITY
Sleep quality was assessed by the 5-item Women’s Health Ini-
tiative Insomnia Rating Scale that was developed and vali-
dated for use in the WHI.35 Items in this survey referenced sleep
during the past 4 weeks. Four items assessed sleep initiation
and maintenance using a 5-point response scale (not in past 4
weeks;1 time/wk; 1-2 times/wk; 3 or 4 times/wk;5 times/
wk). A fifth item assessed sleep quality, also using a 5-point
scale (very sound or restful, sound or restful, average quality,
restless, and very restless). Scores ranged from 0 (worst) to 20
(best).
SEXUAL SATISFACTION
Sexual satisfaction (“How satisfied are you with your current
sexual activities, either with a partner or alone?”) was as-
sessed by a single item with a 4-point response scale (very un-
satisfied, a little unsatisfied, somewhat satisfied, or very satis-
fied). Scores ranged from 1 (worst) to 4 (best).
COGNITIVE FUNCTIONING
Cognitive functioning was assessed in participants 65 years or
older by the Modified Mini-Mental State Examination,36 a scale
used in the Cardiovascular Health Study.37 The Modified Mini-
Mental State Examination has 15 parts with 46 separately scored
items. Maximum (best) scores per item range from 1 to 8 (with
a total of 100). The functions tested are orientation to time, place,
and person; short-term memory; reading; writing; naming; ver-
bal fluency; praxis; and graphomotor performance.
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DEPRESSIVE SYMPTOMS
Depressive symptoms were assessed by means of an 8-item scale38
developed to screen for depressive disorders (major depres-
sion and dysthymia). It included 6 items from the Center for
Epidemiological Studies Depression Scale39 and 2 items from
the Diagnostic Interview Schedule.40 Scores may range from −8.2
(best) to 4.0 (worst). In this questionnaire, a lower score is de-
sirable.
STATISTICAL ANALYSES
All primary analyses focused on changes in HRQOL from base-
line to year 1 in relation to CEE randomization assignment. For
each of the 13 HRQOL measures, we fit a linear model to test
whether CEE had a significant treatment effect on HRQOL
change score. To examine whether the CEE effect was moder-
ated by baseline variables, we fit a series of linear models. Each
pair, a baseline variable and the corresponding CEE interac-
tion, was added one at a time, followed by a test of the inter-
action. Baseline characteristics included age, body mass in-
dex, ethnicity, moderate or severe vasomotor symptoms,
previous hormone therapy use, years since menopause, bilat-
eral oophorectomy status, history of cardiovascular disease, and
socioeconomic variables (education, income, and health in-
surance status). Menopause was defined as the lowest age ac-
cording to last menses, age at bilateral oophorectomy, or age
when hormone therapy was started. If the ovaries were par-
tially removed/intact, menopause was defined as the lower of
the age hormone therapy was started or the age at first meno-
pausal symptoms. Similar analyses were performed on data avail-
able at year 3 for the 8.6% subsample.
Statistical significance of the effect of CEE on HRQOL and
of the tests of interactions were judged by Bonferroni-
correcteds of 0.005 (0.05/13, approximately 0.005) and 0.0005
(approximately 0.05/[1311]), respectively. Actual P values,
unadjusted for multiple comparison, are reported exclusively
throughout the text and tables.
A post hoc analysis examined participants aged 50 to 54 years
who reported moderate to severe night sweats or hot flashes at
baseline. Because P values of treatment effects from subgroups
can be misleading,41 we did not use a Bonferroni-adjusted 
level for this analysis and caution readers to carefully inter-
pret their values. All analyses were based on the intention-to-
treat principle using SAS version 9.1.42
RESULTS
Overall, 5310 women were randomized into the CEE
group and 5429 into the placebo group. The interven-
tion groups were balanced on key demographic charac-
teristics except for a slight statistical difference in bilat-
eral oophorectomy status (Table 1). There were 2.5%
fewer women in the CEE group with bilateral oophorec-
tomy than in the placebo group. The mean age in the co-
hort was 63.6 years; 75.3% were white; 23.9% had a col-
lege education; 48.4% had some previous hormone use;
and 17.3% had moderate/severe vasomotor symptoms at
baseline. Baseline scores on the RAND36 were similar to
scores observed in other healthy populations.43 The scores
were somewhat lower than those seen in the WHI
CEEMPA trial among women with a uterus.5
This analysis focused on changes in HRQOL mea-
sures during the first year of taking study drugs. At year
1, vital status was known for 100% of participants, in-
cluding the 0.4% who died, and none were lost to follow-
up. During the first year, study therapy was stopped for
various reasons by 8.4% of women randomized to CEE
and 8.0% of women randomized to placebo. Overall, 78%
of women randomized to CEE and 82% of women ran-
domized to placebo were adherent (defined as taking
80% of pills) at year 1. At year 3, in the subsample, ad-
herence was 59% for both treatment groups.
In examining the change in HRQOL measures from
baseline to year 1, few differences were observed be-
tween the CEE and placebo groups (Table2). There was
a small (0.40 difference on the 20-point scale) but sta-
tistically significant positive effect of CEE, relative to pla-
cebo, on sleep disturbance (P.001). Based on Co-
hen’s44 rule of thumb, the effect size on sleep (0.4/
3.88=0.1) does not even achieve the threshold for a small
(0.2) effect size. There was also a small but statisti-
cally significant negative effect of CEE on social func-
tioning (P=.003). At year 1, there were no other HRQOL
variables for which a clinically meaningful or statisti-
cally significant improvement was observed with CEE.
Differences from baseline to year 1 in the approxi-
mately 8.6% random subsample of women whose mea-
sures were repeated at year 3 (n=577 in the CEE group;
n=612 in the placebo group) are displayed in Table 3.
Treatment with CEE did not produce a statistically sig-
nificant improvement in any HRQOL variables at year 1
or year 3 in this subsample. Further analyses explored
whether there were substantive effects of CEE on HRQOL
that depended on demographic, health, or other mea-
sures taken at baseline. There were no significant inter-
actions of intervention assignment and any of the follow-
ing: age, race/ethnicity, education, income, insurance status,
body mass index, vasomotor symptoms (moderate or se-
vere night sweats/hot flashes), years since menopause, pre-
vious use of any type of hormone therapy, bilateral oopho-
rectomy status, or history of cardiovascular disease.
Analyses of the following 3 subgroups were of particular
interest: (1) women who had undergone bilateral oopho-
rectomy, (2) women who reported moderate or severe va-
somotor symptoms at baseline (hot flashes or night sweats),
and (3) the youngest age group (with symptoms). These
subgroups may have experienced greater improvements
in QOL from relief of symptoms by CEE. There was no
significant difference in the effect of CEE on HRQOL among
women who had undergone bilateral oophorectomy com-
pared with those who had not. Apart from HRQOL, we
examined the effects of CEE on relief of symptoms spe-
cifically among women who reported moderate or severe
vasomotor symptoms at baseline (913 women in the CEE
and 917 in the placebo groups). At the 1-year follow-up,
72.4% of women reporting moderate or severe vasomo-
tor symptoms at baseline in the CEE group no longer re-
ported them, compared with 55.6% of women in the pla-
cebo group (P.001). As shown in Table4, an additional
restriction to women aged 50 to 54 years reporting mod-
erate or severe vasomotor symptoms at baseline does not
magnify any positive effect of CEE on HRQOL variables.
For 7 of the 13 HRQOL changes (baseline to year 1), these
youngest participants in the CEE group had worse scores
than the placebo group. A higher proportion of partici-
pants in the placebo group (39%) reported, at year 1, much
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better or somewhat better health than participants in the
CEE group (23%) (Table 5).
The single global item asked: “Overall, how would you
rate your quality of life?” The distributions of global scores
did not differ between the CEE and placebo groups (data
not shown). In both groups, less than 3% reported poor
and 40% reported excellent global QOL. The CEE and pla-
cebo groups were very similar in the proportions of par-
ticipants who rated their global QOL in the moderate and
good categories (26%-30%). Table 6 offers a sense of the
Table 1. Baseline Characteristics by Treatment Assignment (Missing Excluded)
Characteristic
Treatment, No. (%)
P
ValueCEE Group
Placebo
Group
Age at screening, y
50-54 687 (12.9) 709 (13.1)
55-59 950 (17.9) 964 (17.8)
.94
60-69 2387 (45.0) 2465 (45.4)
70-79 1286 (24.2) 1291 (23.8)
Ethnicity
White 4007 (75.5) 4075 (75.1)
Black 782 (14.7) 835 (15.4)
Hispanic 322 (6.1) 333 (6.1)
.81
American Indian 41 (0.8) 34 (0.6)
Asian/Pacific Islander 86 (1.6) 78 (1.4)
Unknown 72 (1.4) 74 (1.4)
BMI (collapsed categories)
25 1110 (21.0) 1096 (20.3)
25-30 1795 (34.0) 1912 (35.5) .26
30 2376 (45.0) 2383 (44.2)
Education
0-8 y 181 (3.4) 148 (2.7)
Some high school 354 (6.7) 370 (6.9)
High school diploma/GED 1233 (23.5) 1188 (22.1) .06
School after high school 2271 (43.2) 2350 (43.7)
College degree or higher 1216 (23.1) 1327 (24.7)
Annual family income, $
10 000 423 (8.4) 441 (8.6)
10 000-19 999 999 (19.9) 990 (19.4)
20 000-34 999 1492 (29.8) 1507 (29.5)
.90
35 000-49 999 947 (18.9) 1000 (19.6)
50 000-74 999 725 (14.5) 722 (14.1)
75 000 422 (8.4) 444 (8.7)
Age at hysterectomy, y
40 2100 (39.8) 2149 (39.8)
40-49 2281 (43.2) 2275 (42.2)
.34
50-54 501 (9.5) 566 (10.5)
55 401 (7.6) 404 (7.5)
Years since menopause
5 330 (7.3) 325 (7.0)
5 to 10 496 (11.0) 492 (10.6)
.83
10 to 15 704 (15.7) 734 (15.8)
15 2963 (65.9) 3085 (66.5)
Duration of previous hormone use, y
0 2769 (52.1) 2770 (51.0)
5 1352 (25.5) 1412 (26.0)
.53
5 to 10 469 (8.8) 515 (9.5)
10 720 (13.6) 732 (13.5)
Baseline moderate/severe vasomotor symptoms
No 4327 (82.6) 4431 (82.9)
.71
Yes 913 (17.4) 917 (17.1)
History of CVD
No 4768 (90.9) 4893 (91.3)
.53
Yes 477 (9.1) 469 (8.7)
Prior bilateral oophorectomy
No 2973 (60.5) 2917 (58.0)
.01
Yes 1938 (39.5) 2111 (42.0)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CEE, conjugated equine estrogen;
CVD, cardiovascular disease; GED, General Educational Development test.
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metric for HRQOL (eg, RAND36 scores) by showing dif-
ferences that are associated with categorical increments in
global QOL. As examples, the HRQOL mean scores were
approximately1SDhigher forwomenwhorated their global
QOL as excellent compared with those who rated it as mod-
erate. The HRQOL sleep disturbance score was 3 points
higher (less disturbance) for women rating their global QOL
as excellent compared with those who rated it as moder-
ate. Higher ratings of global QOL were associated with
higher scores on each of the RAND36 subscales and lower
scores on the depression measures, all suggesting that this
global item is sensitive to symptoms and functioning. Also,
regardless of treatment assignment, moderate to severe
menopausal symptoms and adverse effects of hormone
therapywere significantlyassociatedwithworseglobalQOL.
Because of the slight imbalance of bilateral oophorec-
tomy status by treatment assignment, we performed a sen-
sitivity analysis of our primary results. Adjustment of bi-
lateral oophorectomy status did not change conclusions
regarding sleep disturbance; the mean difference be-
tween the CEE and placebo groups changed from 0.40
to 0.38 and remained statistically significant (P.001).
However, oophorectomy adjustment slightly attenu-
ated the effect of CEE on social functioning; after adjust-
ment, the mean difference changed from −1.31 to −1.16
(P=.01) and consequently did not reach the Bonferroni-
corrected level. None of the other results were changed
after adjusting for bilateral oophorectomy status.
COMMENT
In the WHI RCT of CEE alone,4 a clinically meaningful
benefit of CEE treatment on HRQOL was not found in
Table 2. Change in QOL Scores From Baseline to Year 1
Variable
CEE Group Placebo Group Difference
No. of
Subjects
Mean (SD)
Score
No. of
Subjects
Mean (SD)
Score Mean (SE)
P
Value
General health*
Baseline 5210 71.95 (17.97) 5334 72.38 (18.05) −0.43 (0.35) .22
Year 1 4654 −0.31 (13.71) 4767 −0.37 (14.24) 0.07 (0.29) .82
Physical functioning*
Baseline 5185 76.47 (21.98) 5297 77.23 (21.76) −0.77 (0.43) .07
Year 1 4580 −1.20 (15.57) 4678 −1.89 (15.81) 0.69 (0.33) .04
Role physical*
Baseline 5226 70.49 (36.75) 5356 70.22 (36.94) 0.27 (0.72) .70
Year 1 4664 −2.04 (38.30) 4783 −1.81 (38.58) −0.23 (0.79) .77
Bodily pain*
Baseline 5251 70.67 (24.65) 5384 70.75 (24.85) −0.08 (0.48) .87
Year 1 4764 −1.22 (22.76) 4885 −1.98 (22.94) 0.76 (0.47) .11
Vitality*
Baseline 5217 60.55 (20.00) 5324 61.04 (20.23) −0.49 (0.39) .21
Year 1 4662 −0.14 (16.04) 4757 −0.02 (16.36) −0.12 (0.33) .72
Social functioning*
Baseline 5245 88.61 (18.76) 5366 88.10 (19.47) 0.51 (0.37) .17
Year 1 4736 −3.09 (21.98) 4836 −1.77 (21.75) −1.31 (0.45) .003†
Role emotional*
Baseline 5242 81.56 (31.89) 5366 82.17 (31.12) −0.61 (0.61) .32
Year 1 4682 −1.56 (33.99) 4801 −0.43 (33.63) −1.13 (0.69) .10
Mental health*
Baseline 5220 77.37 (15.58) 5335 77.90 (15.26) −0.54 (0.30) .08
Year 1 4651 0.60 (13.28) 4750 0.56 (13.32) 0.03 (0.27) .91
Depressive symptoms‡
Baseline 5103 −5.21 (2.08) 5231 −5.24 (2.06) 0.03 (0.04) .51
Year 1 4465 −0.17 (1.93) 4599 −0.13 (1.91) −0.04 (0.04) .33
3MSE*
Baseline 1784 94.28 (5.02) 1788 94.33 (5.13) −0.05 (0.17) .77
Year 1 1637 0.47 (6.45) 1648 0.87 (4.14) −0.39 (0.19) .04
Sleep disturbance§
Baseline 5178 12.54 (4.76) 5284 12.71 (4.73) −0.17 (0.09) .07
Year 1 4574 0.46 (3.84) 4670 0.07 (3.88) 0.40 (0.08) .001†
Satisfaction with sex||
Baseline 4206 2.91 (1.10) 4256 2.93 (1.09) −0.02 (0.02) .43
Year 1 3314 0.01 (1.13) 3368 0.02 (1.12) −0.01 (0.03) .65
Abbreviations: CEE, conjugated equine estrogen; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life.
*Scored from 0 (worst) to 100 (best).
†P value is statistically significant at Bonferroni corrected  level of 0.005; in all tables actual, unadjusted P values are presented.
‡Scored from 4.0 (worst) to −8.1 (best).
§Scored from 0 (worst) to 20 (best).
||Scored from 0 (worst) to 4 (best).
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an ethnically diverse population of postmenopausal
women who had undergone hysterectomy before enter-
ing the study. Failure to demonstrate global improve-
ment in HRQOL occurred, despite absence of uterine
bleeding or other progestin-associated adverse effects.
These results were similar to results reported for
women with a uterus in the WHI CEEMPA trial.5 In
both trials, a statistically significant, small improve-
ment in average sleep disturbance score was found after
1 year of hormone treatment. Women with vasomotor
symptoms experienced a significant decline in these symp-
toms, but the positive effects on physical functioning and
bodily pain seen in the WHI CEEMPA trial were not
found here.
Table 3. Change in QOL Scores at Years 1 and 3 Compared With Baseline in CEE Subgroup of 1189 Participants
Variable
CEE Group Placebo Group Difference
No. of
Subjects
Mean (SD)
Score
No. of
Subjects
Mean (SD)
Score Mean (SE)
P
Value
General health*
Baseline 559 71.06 (18.61) 596 71.38 (17.74) −0.33 (1.07) .76
Year 1 488 −1.88 (14.89) 519 −0.47 (14.53) −1.40 (0.93) .13
Year 3 475 −3.51 (14.85) 487 −2.90 (15.12) −0.61 (0.97) .53
Physical functioning*
Baseline 554 75.60 (22.87) 593 77.56 (20.89) −1.97 (1.29) .13
Year 1 475 −1.65 (16.35) 513 −2.72 (16.75) 1.07 (1.05) .31
Year 3 456 −4.67 (18.91) 483 −6.21 (19.08) 1.54 (1.24) .22
Role physical*
Baseline 563 68.83 (36.75) 602 70.02 (37.08) −1.19 (2.16) .58
Year 1 492 −2.29 (40.69) 527 −1.42 (40.35) −0.86 (2.54) .73
Year 3 476 −5.78 (40.69) 490 −6.73 (42.19) 0.96 (2.67) .72
Bodily pain*
Baseline 563 70.71 (24.74) 606 70.75 (24.79) −0.04 (1.45) .98
Year 1 505 −1.51 (24.04) 538 −2.37 (24.12) 0.86 (1.49) .56
Year 3 479 −4.62 (24.33) 500 −5.33 (25.37) 0.71 (1.59) .66
Vitality*
Baseline 558 60.08 (19.89) 593 60.95 (20.55) −0.87 (1.19) .47
Year 1 484 −0.59 (15.41) 516 0.66 (17.26) −1.25 (1.04) .23
Year 3 471 −1.28 (16.36) 483 −2.26 (18.54) 0.97 (1.13) .39
Social functioning*
Baseline 562 88.19 (18.67) 604 87.44 (19.55) 0.75 (1.12) .50
Year 1 499 −3.83 (23.66) 534 −1.73 (22.14) −2.10 (1.42) .14
Year 3 476 −4.86 (23.59) 501 −3.62 (23.29) −1.24 (1.50) .41
Role emotional*
Baseline 567 78.31 (33.36) 602 79.84 (32.35) −1.54 (1.92) .42
Year 1 494 −2.16 (37.32) 526 0.25 (33.68) −2.41 (2.22) .28
Year 3 478 −1.74 (37.75) 496 −3.90 (39.16) 2.15 (2.47) .38
Mental health*
Baseline 559 77.14 (15.93) 597 77.09 (15.31) 0.05 (0.92) .96
Year 1 487 −0.34 (13.11) 522 0.90 (13.93) −1.25 (0.85) .14
Year 3 472 −0.45 (14.76) 483 0.17 (14.74) −0.61 (0.95) .52
Depressive symptoms†
Baseline 545 −5.18 (2.06) 579 −5.29 (2.01) 0.11 (0.12) .36
Year 1 460 −0.18 (2.09) 498 0.03 (1.93) −0.21 (0.13) .11
Year 3 453 −0.10 (2.09) 464 −0.06 (2.17) −0.04 (0.14) .77
3MSE*
Baseline 194 93.07 (5.09) 200 92.70 (5.49) 0.37 (0.53) .49
Year 1 180 0.67 (8.56) 177 0.97 (3.99) −0.30 (0.71) .67
Year 3 172 1.52 (4.18) 166 1.30 (5.01) 0.23 (0.50) .65
Sleep disturbance‡
Baseline 561 12.96 (4.72) 592 12.97 (4.71) −0.02 (0.28) .96
Year 1 489 0.18 (3.89) 517 0.00 (4.00) 0.18 (0.25) .47
Year 3 464 0.00 (4.32) 480 −0.20 (4.22) 0.20 (0.28) .48
Satisfaction with sex§
Baseline 456 2.89 (1.11) 453 2.80 (1.13) 0.09 (0.07) .21
Year 1 354 −0.07 (1.19) 348 0.07 (1.07) −0.15 (0.09) .09
Year 3 324 0.01 (1.22) 325 0.04 (1.18) −0.03 (0.09) .74
Abbreviations: CEE, conjugated equine estrogen; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life.
*Scored from 0 (worst) to 100 (best).
†Scored from 4.0 (worst) to −8.1 (best).
‡Scored from 0 (worst) to 20 (best).
§Scored from 0 (worst) to 4 (best).
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Several baseline differences in HRQOL were noted be-
tween women in the CEEMPA trial (with a uterus) and
women in the CEE trial (without a uterus). The average
bodily pain score at baseline was significantly more nega-
tive (more pain) in the CEE trial than in the CEEMPA
trial (P.001). Similarly, women in the CEE trial had
worse physical functioning scores at baseline (P.001).
Also, in the CEEMPA trial, at baseline, fewer women
reported poor and more reported excellent global QOL
than in the present trial (P.001). However, after 1 year,
the CEE and CEEMPA groups did not differ from their
respective placebo groups in global QOL. The sub-
sample with HRQOL undergoing reassessment 3 years
from baseline provided no evidence that longer-term use
of CEE improves HRQOL measures compared with a
shorter-term use. It could be argued that the limited ef-
fects of CEE on HRQOL resulted from a too conserva-
tive  level probability threshold, one that had been ad-
justed for multiple comparisons. However, we have
presented actual (unadjusted) P values, so the reader may
decide what they consider statistically significant. For ex-
ample, applying a liberal  value of .05 would only add
a statistically significant improvement in physical func-
tioning from CEE, which then is perhaps offset by a sig-
nificant negative change in cognitive functioning.
The minimal benefit of CEE on HRQOL (2% improve-
ment in sleep disturbance symptoms) does not chal-
lenge the current treatment guidelines. The findings sug-
gest that asymptomatic women using estrogen therapy,
eg, for prevention of osteoporosis, are unlikely in the short
term to experience a meaningful improvement in HRQOL.
Overall, our results are consistent with other recent ran-
domized trials46,47 and epidemiological studies.48 The WHI
and other studies indicate that some menopausal vasomo-
tor symptoms improve with estrogen treatment. There is
little or no benefit of systemic hormone treatment for most
otherphysical, functional, andpsychosocial conditions,with
some, like nocturnal urinary frequency, worsening.49,50 The
HRQOL measures may be considered subjective aggre-
gates that are complexly influenced by the combination of
Table 4. Changes in QOL Scores From Baseline to Year 1 Among Subjects Aged 50 to 54 Years
With Moderate or Severe Vasomotor Symptoms
Subscale
CEE Group Placebo Group Difference
No. of
Subjects
Mean (SD)
Score
No. of
Subjects
Mean (SD)
Score Mean (SE)
P
Value
General health* 162 −0.52 (14.87) 162 1.82 (15.47) −2.35 (1.69) .17
Physical functioning* 165 −0.61 (17.21) 156 −0.51 (21.37) −0.09 (2.16) .97
Role physical* 167 −1.35 (40.07) 163 2.91 (40.96) −4.26 (4.46) .34
Bodily pain* 169 −4.36 (24.93) 165 0.45 (26.00) −4.82 (2.79) .09
Vitality* 166 1.23 (18.73) 161 0.84 (18.94) 0.40 (2.08) .85
Social functioning* 167 −2.17 (26.99) 165 0.45 (23.14) −2.63 (2.76) .34
Role emotional* 167 1.00 (36.30) 164 0.41 (38.01) 0.59 (4.08) .89
Mental health* 167 1.08 (16.50) 163 0.59 (15.96) 0.49 (1.79) .79
Depressive symptoms† 159 −0.15 (2.63) 151 0.08 (2.59) −0.23 (0.30) .44
Sleep disturbance‡ 165 1.35 (4.60) 157 0.53 (4.59) 0.82 (0.51) .11
Satisfaction with sex§ 140 −0.07 (1.12) 134 0.02 (1.17) −0.09 (0.14) .50
Abbreviations: CEE, conjugated equine estrogen; QOL, quality of life.
*Scored from 0 (worst) to 100 (best).
†Scored from 4.0 (worst) to −8.1 (best).
‡Scored from 0 (worst) to 20 (best).
§Scored from 0 (worst) to 4 (best).
Table 5. Change in Rating of General Health*
Response
Overall†
Subjects Aged 50-54 Years With
Moderate/Severe Vasomotor Symptoms†
CEE Group Placebo Group CEE Group Placebo Group
Much better now 368 (7.6) 323 (6.6) 9 (5.2) 21 (12.7)
Somewhat better now 754 (15.6) 738 (15.0) 31 (18.0) 43 (25.9)
About the same 3075 (63.7) 3156 (64.3) 104 (60.5) 76 (45.8)
Somewhat worse now 589 (12.2) 646 (13.2) 25 (14.5) 24 (14.5)
Much worse now 38 (0.8) 47 (1.0) 3 (1.7) 2 (1.2)
Abbreviation: CEE, conjugated equine estrogen.
*Indicates answers to the question “Compared to 1 year ago, how would you rate your general health now?” Excludes missing subjects. Data are given as
number (percentage). Percentages have been rounded and may not total 100.
†P.01 between treatment groups, based on 2-sided Cochran-Armitage test for trend to determine whether active treatment is associated with an increasing or
decreasing health-related quality of life at year 1.
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estrogen replacement’s improvement in vasomotor symp-
toms (and/or other unspecified positive effects), adverse
effects, and consequences for disease processes and end
points. Part of the rationale for the original study design
was that estrogen would have health benefits (bone, heart,
and cognition) that would be reflected in HRQOL mea-
sures. The absence of an improvement with estrogen in
the global index, the study’s overall risk-benefit health
profile,4 may help explain the weak response of HRQOL
measures.
As a randomized clinical trial of relatively healthy
women after menopause, it might be argued that the po-
tential for positive health differences was limited by a
“ceiling” that effectively reduced the range of scores at
the upper end of the spectrum. This may be the case for
the 2-item social functioning subscale (mean score
lower in the CEE group) of the RAND36, which has a
coarse Likert scale. Most participants attained the maxi-
mum score on social functioning. For other subscales,
average scores were well below the possible maximum.
For example, only 1% of subjects had maximum vitality
scores, and baseline HRQOL scores were generally
lower in this population than in the previously reported
CEEMPA trial in women without a hysterectomy.
We attribute the latter difference largely to more health
risk factors and lower socioeconomic status in the
women with hysterectomy.
Some reports suggest that estrogen therapy might play
a role in the management of severe emotional and mental
changes in the postpartum or perimenopausal peri-
ods.51,52 The impact of estrogen treatment in clinical mood
disorders may be very different than its population effects
in healthy women not selected for such disturbances.
Estrogen therapy alone in women with a hysterec-
tomy did not produce clinically meaningful improve-
ments in HRQOL measures compared with placebo, de-
spite reduction of some vasomotor symptoms resulting
from the active treatment, albeit in the relatively small
proportion of women in the cohort who were symptom-
atic. Any overall impact may have been lessened by the
size of the specific effect on sleep disturbance, which, as
one of the more widely reported and enduring prob-
lems in this age group, had only a small average improve-
ment, perhaps because nocturnal urinary frequency may
worsen with hormone treatment.49 Moreover, recent re-
views have suggested that subjectively reported sleep dis-
Table 6. Relationship of Vasomotor Symptoms, Adverse Effects of Treatment, and RAND36 Scores
to Global QOL at Year 1 Collapsed by Treatment Assignment
Variable
Global QOL Rating at Year 1
Poor
(n = 235)
Moderate
(n = 2671)
Good
(n = 2884)
Excellent
(n = 3944)
Events through year 1, No. (%) of subjects*† 2 (0.9) 40 (1.5) 26 (0.9) 24 (0.6)
Prevalence of moderate/severe symptoms at year 1‡
Vasomotor symptoms§ 66 (29.1) 428 (16.2) 265 (9.3) 293 (7.5)
Vaginal dryness 32 (13.9) 283 (10.8) 221 (7.7) 258 (6.6)
General aches and pains 160 (69.6) 1265 (47.9) 916 (32.1) 708 (18.1)
Joint pain and stiffness 150 (64.7) 1225 (46.6) 941 (32.9) 820 (20.9)
Prevalence of moderate/severe adverse effects at year 1||
Breast tenderness 28 (12.2) 242 (9.1) 177 (6.2) 209 (5.3)
Vaginal discharge 8 (3.5) 75 (2.8) 62 (2.2) 58 (1.5)
Vaginal itch 22 (9.5) 226 (8.6) 153 (5.3) 171 (4.4)
Headache 63 (27.4) 476 (18.0) 327 (11.4) 352 (9.0)
Other HRQOL variables, mean (SD) scores¶
General health 48.0 (21.0) 61.3 (18.3) 72.3 (15.4) 80.8 (14.9)
Physical functioning 51.7 (30.6) 65.5 (26.1) 76.6 (21.1) 83.0 (18.8)
Role physical 33.5 (37.4) 52.5 (41.1) 69.5 (37.3) 81.8 (31.0)
Bodily pain 43.6 (28.8) 58.5 (27.0) 69.7 (23.4) 78.3 (21.5)
Vitality 27.2 (20.0) 48.3 (20.0) 61.1 (17.9) 71.5 (16.3)
Social functioning 52.7 (28.5) 75.9 (24.4) 88.5 (18.3) 93.8 (14.2)
Role emotional 40.1 (38.5) 67.4 (38.5) 85.2 (28.5) 91.0 (23.1)
Mental health 49.5 (19.2) 68.6 (16.8) 79.9 (12.4) 86.2 (10.9)
Depressive symptoms −2.2 (2.8) −4.5 (2.4) −5.6 (1.6) −6.1 (1.3)
3MSE 93.7 (14.0) 94.1 (7.0) 95.3 (4.6) 95.2 (5.2)
Sleep disturbance 9.9 (5.4) 11.3 (4.9) 12.9 (4.5) 14.3 (4.3)
Satisfaction with sex 2.4 (1.1) 2.7 (1.1) 3.0 (1.0) 3.1 (1.1)
Abbreviations: HRQOL, health-related QOL; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life; RAND36, RAND 36-Item Health Survey.
*Includes myocardial infarction, hip fracture, invasive breast cancer, colon cancer, stroke, and pulmonary embolism before their year 1 QOL data were collected.
†P.001 based on 1-sided Cochran-Armitage test for linear trend to test whether higher prevalence of symptoms and higher incidence of events are associated
with lower global QOL.
‡These symptoms were identified a priori and are based on the Women’s Health Initiative conjugated estrogen and medroxyprogesterone acetate gynecological
symptoms data).45
§Includes hot flashes and/or night sweats.
||These effects were identified a priori based on the Women’s Health Initiative conjugated estrogen and medroxyprogesterone acetate gynecological symptoms
data.45
¶P.001 based on 1-sided test for linear trend to determine whether higher HRQOL scores are associated with higher global QOL scores.
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turbance during and after menopause has multiple causes
and that its relationship to hormone changes is com-
plex.53,54 In the WHI, health risks and benefits were rela-
tively balanced after more than 6 years of CEE use. In-
dividual women may experience some improvement in
their vasomotor and urogenital atrophy symptoms, but
these may be partly offset by adverse effects associated
with postmenopausal hormone treatment. We find no evi-
dence of an HRQOL benefit for the general postmeno-
pausal population.
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